

CITATION REPORT

List of articles citing

Slow Titration of Cannabidiol Add-On in Drug-Resistant Epilepsies Can Improve Safety With Maintained Efficacy in an Open-Label Study

DOI: 10.3389/fneur.2020.00829
Frontiers in Neurology, 2020, 11, 829.

Source: <https://exaly.com/paper-pdf/75832681/citation-report.pdf>

Version: 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
18	Safety considerations selecting antiseizure medications for the treatment of individuals with Dravet syndrome. <i>Expert Opinion on Drug Safety</i> , 2021 , 20, 561-576	4.1	4
17	Highly Purified Cannabidiol for Epilepsy Treatment: A Systematic Review of Epileptic Conditions Beyond Dravet Syndrome and Lennox-Gastaut Syndrome. <i>CNS Drugs</i> , 2021 , 35, 265-281	6.7	7
16	Pharmacotherapy for Seizures in Tuberous Sclerosis Complex. <i>CNS Drugs</i> , 2021 , 35, 965-983	6.7	1
15	Review of the treatment options for epilepsy in tuberous sclerosis complex: towards precision medicine. <i>Therapeutic Advances in Neurological Disorders</i> , 2021 , 14, 17562864211031100	6.6	3
14	Cannabinoids in the Treatment of Epilepsy: A Review. <i>European Medical Journal (Chelmsford, England)</i> ,	7.5	
13	Benefits, toxicity and current market of cannabidiol in edibles.. <i>Critical Reviews in Food Science and Nutrition</i> , 2022 , 1-13	11.5	1
12	The importance of drug titration in the management of patients with epilepsy.. <i>Epilepsy and Behavior</i> , 2022 , 128, 108517	3.2	1
11	A scoping review on cannabidiol therapy in tuberous sclerosis: Current evidence and perspectives for future development.. <i>Epilepsy and Behavior</i> , 2022 , 128, 108577	3.2	2
10	A Practical Guide to the Treatment of Dravet Syndrome with Anti-Seizure Medication.. <i>CNS Drugs</i> , 2022 , 36, 217	6.7	3
9	Onset of efficacy and adverse events during Cenobamate titration period. <i>Acta Neurologica Scandinavica</i> ,	3.8	0
8	Statement on safety of cannabidiol as a novel food: data gaps and uncertainties. <i>EFSA Journal</i> , 2022 , 20,	2.3	1
7	Treatment strategies for Lennox-Gastaut syndrome: outcomes of multimodal treatment approaches. 2022 , 15, 175628642211080		
6	Cannabis-based magistral formulation is highly effective as an adjuvant treatment in drug-resistant focal epilepsy in adult patients: an open-label prospective cohort study.		0
5	Fenfluramine for Treating Dravet Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.		0
4	Neue Aspekte zur Therapie des Dravet-Syndroms. 2022 , 22, 324-332		0
3	Overview of therapeutic options for epilepsy. 2022 , 29, 5S14-5S19		0
2	Cannabidiol-associated hepatotoxicity: A systematic review and meta-analysis.		0

- 1 Adverse Events of Cannabidiol Use in Patients With Epilepsy. **2023**, 6, e239126

o